Table 4.
| Estimated hazard ratios from a proportional hazards model of overall survival with erythropoietin exposure considered a time-dependent factor | |||
|---|---|---|---|
| Covariate | Hazard ratio | 95% Confidence interval | p-value |
| Erythropoietin (time-dependent) | 0.989 | 0.849 – 1.15 | 0.892 |
| Performance Status 0 | 1.00 | < 0.001 | |
| Performance Status 1 | 1.37 | 1.19 – 1.58 | |
| Performance Status 2 | 2.37 | 1.84 – 2.95 | |
| Stage III (≤ 1 cm residual) | 1.00 | < 0.001 | |
| Stage III (> 1 cm residual) | 1.43 | 1.21 – 1.70 | |
| Stage IV | 1.60 | 1.33 – 1.926 | |
| HGB < 10 | 1.00 | 0.093 | |
| 10 ≤ HGB ≤ 12 | 1.01 | 0.798 – 1.286 | |
| HGB > 12 | 0.863 | 0.672 – 1.109 | |
| Estimated hazard ratios from a proportional hazards model of overall survival with GCSF exposure considered a time-dependent factor | |||
|---|---|---|---|
| Covariate | Hazard ratio | 95% Confidence interval | p-value |
| GCSF (time-dependent) | 0.932 | 0.800 – 1.08 | 0.363 |
| Performance Status 0 | 1.00 | < 0.001 | |
| Performance Status 1 | 1.36 | 1.18 – 1.56 | |
| Performance Status 2 | 2.37 | 1.88 – 2.99 | |
| Stage III (≤ 1 cm residual) | 1.00 | < 0.001 | |
| Stage III (> 1 cm residual) | 1.43 | 1.21 – 1.70 | |
| Stage IV | 1.60 | 1.33 – 1.92 | |
| WBC < 10 | 1.00 | 0.027 | |
| 10 ≤ WBC ≤ 12 | 1.24 | 0.780 – 1.98 | |
| WBC > 12 | 1.50 | 0.956 – 2.34 | |